PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…
Matched conditions: PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to shrink advanced stomach tumors
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …
Matched conditions: PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Matched conditions: PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC